| Targeting the TGFβ signalling pathway in disease | 2012/09/24 | English | 1,048 |
| The exploration of macrocycles for drug discovery — an underexploited structural class | 2008/07/01 | English | 1,033 |
| MicroRNAs and other non-coding RNAs as targets for anticancer drug development | 2013/10/31 | English | 1,023 |
| The IKK NF-κB system: a treasure trove for drug development | 2004/01/01 | English | 1,022 |
| Adenosine receptors as therapeutic targets | 2006/03/01 | English | 1,018 |
| Drug–target residence time and its implications for lead optimization | 2006/08/04 | English | 1,017 |
| The COVID-19 vaccine development landscape | 2020/04/09 | English | 1,009 |
| Epigenetic protein families: a new frontier for drug discovery | 2012/04/13 | English | 996 |
| Nanosuspensions in drug delivery | 2004/09/01 | English | 993 |
| Structural diversity of G protein-coupled receptors and significance for drug discovery | 2008/04/01 | English | 985 |
| Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | 2006/02/01 | English | 983 |
| Targeting IL-17 and TH17 cells in chronic inflammation | 2012/10/01 | English | 967 |
| Advances in oligonucleotide drug delivery | 2020/08/11 | English | 964 |
| Targeting oxidative stress in disease: promise and limitations of antioxidant therapy | 2021/06/30 | English | 955 |
| Platforms for antibiotic discovery | 2013/04/30 | English | 953 |
| Turning foes to friends: targeting cancer-associated fibroblasts | 2018/11/23 | English | 945 |
| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug | 2002/07/01 | English | 942 |
| Targeting bile-acid signalling for metabolic diseases | 2008/08/01 | English | 940 |
| Anti-virulence strategies to combat bacteria-mediated disease | 2010/01/18 | English | 935 |
| Targeting the NLRP3 inflammasome in inflammatory diseases | 2018/07/20 | English | 931 |
| Targeting bromodomains: epigenetic readers of lysine acetylation | 2014/04/22 | English | 928 |
| Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | 2010/10/29 | English | 925 |
| Targeting proteases: successes, failures and future prospects | 2006/09/01 | English | 923 |
| Therapeutic potential of Toll-like receptor 9 activation | 2006/06/01 | English | 920 |
| Combination cancer immunotherapy and new immunomodulatory targets | 2015/07/31 | English | 919 |
| In vivo drug discovery in the zebrafish | 2005/01/01 | English | 916 |
| Oncolytic viruses: a new class of immunotherapy drugs | 2015/09/01 | English | 898 |
| Bio-inspired, bioengineered and biomimetic drug delivery carriers | 2011/07/01 | English | 894 |
| Current status and future potential of transdermal drug delivery | 2004/02/01 | English | 893 |
| p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases | 2003/09/01 | English | 887 |